Nanotrope Inc.
This article was originally published in Start Up
Executive Summary
Nanotrope produces precise nanoscale droplets from the continuous flow of immiscible fluids using a microfluidic device. The company sees many potential applications for its technology, but it is pursuing its use for drug delivery. Nanotrope aims to provide a better way of delivering and stabilizing macromolecular drugs to improve their safety and efficacy profiles.
You may also be interested in...
One Small Step for FDA...
FDA is building a knowledge base in nanotechnology and testing its current regulatory procedures. But adapting to the new field could stress the agency's already tight resources and may damage its fragile credibility with the public.
What Nanotech Means to Health Care Investors
If there's a common theme being articulated by CEOs of nanobiotechnology start-ups, it's that, at least financially, life has been difficult because they're early stage. Indeed, the nanotech label is less significant to health care investors than considerations related to their business strategy. Drug-delivery-oriented nanobiotechs, for example, must be strongly product focused to avoid the implications that they have an old, low-value model.
Biodesy LLC
Second-harmonic generation is an optical phenomenon that occurs when a nonlinear surface combines photons of light to produce photons with twice the frequency and half the wavelength of the original photons. Biodesy is harnessing its power to measure protein conformation for drug discovery.